look news india
Torrent Pharmaceuticals Ltd on Wednesday announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialise its drug, Vonoprazone, in the Indian market. Vonoprazone is a novel potassium competitive acid blocker (p-CAB) used to treat acid-related disorders – gastroesophageal reflux disease (GERD). Torrent will market Vonoprazone under its trademark Kabvi.
Commenting on the agreement, Aman Mehta, Director, Torrent, said, “We are delighted to commercialize this innovative treatment for Indian patients. I am confident that the launch of Kabvi will help reduce the disease burden of GERD and strengthen our gastrointestinal offering, enhancing our position as a leading player in the Indian pharmaceuticals market.
According to a 2019 study published by the Indian Journal of Gastroenterology, the prevalence of GERD in the Indian population is around 8.2 percent. Which is about 11.1 percent more than the urban population. According to WACS MAT April 2024 data, the Indian market for treatments used in GERD is Rs 8,064 crore. Which is growing at a CAGR of 8 percent in the last four years. Currently, treatments like pantoprazole (proton pump inhibitor) are used to treat GERD.
